Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers

To characterize the safety and tolerability, identify recommended doses and regimens for future studies, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of LSZ102 as a single agent and in combination with either LEE011 or BYL719 in adult patients with locally advanced or metastatic ER+ breast cancer who have progressed after endocrine therapy.

Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT02734615.

Trial PhasePhase I

Trial Typetreatment

Lead OrganizationNovartis Pharmaceuticals Corporation

• Primary IDCLSZ102X2101
• Secondary IDsNCI-2016-00957, 2015-004016-38
• ClinicalTrials.gov IDNCT02734615